Literature DB >> 21995622

Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients.

Fred Poordad1, Dickens Theodore, Jane Sullivan, Kelly Grotzinger.   

Abstract

OBJECTIVE: Thrombocytopenia (TCP), defined as platelet counts <150,000/µL, is a common complication of severe chronic liver disease (CLD). This retrospective study estimated the prevalence of thrombocytopenia in a large population of CLD patients and compared medical resource utilization and medical care costs by TCP status.
METHODS: A retrospective analysis was conducted on a longitudinal administrative claims database from a large US commercial health plan. Patients assigned CLD diagnosis codes from January 1, 2000-December 31, 2003 were identified; annual ambulatory visits, ER visits, inpatient stays, and general and CLD-related medical care costs for patients with vs without TCP (identified using diagnosis codes and platelet count data if available) were compared.
RESULTS: Of 56,445 patients with an ICD-9-CM diagnosis for CLD, 1289 (2.3%) had a diagnosis for TCP. CLD patients with vs without a TCP diagnosis had >2.5-times the annual number of liver disease-related ambulatory visits (3.6 vs 1.4; odds ratio [OR] = 2.6, p < 0.01); were 13-times more likely to have a liver-related inpatient stay (OR = 13.0, p < 0.01); were nearly 4-times more likely to have a liver-related ER visit (OR = 3.9, p < 0.01); had 3.5-fold greater mean annual overall medical care costs ($43,560 vs $12,270, p < 0.01); and had 7-fold greater annual liver disease-related medical care costs ($9940 vs $1420, p < 0.01). Similar results were seen for patients with platelet count data indicating TCP. LIMITATIONS: CLD and TCP are not always diagnosed, nor is diagnosis uniform or standardized; administrative claims data are subject to coding errors, and individuals covered are not necessarily representative of the general US population. The number of CLD patients in this study with TCP (n = 1289) is small relative to that expected in the general US population.
CONCLUSIONS: In this analysis, CLD patients with TCP used significantly more medical resources and incurred significantly higher medical care costs than those without TCP.

Entities:  

Mesh:

Year:  2011        PMID: 21995622     DOI: 10.3111/13696998.2011.632463

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  3 in total

Review 1.  Management of Thrombocytopenia in Patients with Chronic Liver Disease.

Authors:  Sammy Saab; Robert S Brown
Journal:  Dig Dis Sci       Date:  2019-04-22       Impact factor: 3.199

2.  Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.

Authors:  Nigel Armstrong; Nasuh Büyükkaramikli; Hannah Penton; Rob Riemsma; Pim Wetzelaer; Vanesa Huertas Carrera; Stephanie Swift; Thea Drachen; Heike Raatz; Steve Ryder; Dhwani Shah; Titas Buksnys; Gill Worthy; Steven Duffy; Maiwenn Al; Jos Kleijnen
Journal:  Health Technol Assess       Date:  2020-10       Impact factor: 4.014

3.  Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures.

Authors:  Giulia Mastrorilli; Francesca Fiorentino; Carmen Tucci; Gloria Lombardi; Alessio Aghemo; Giorgio L Colombo
Journal:  Clinicoecon Outcomes Res       Date:  2022-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.